Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Studying the metabolic pathways of cholesterol from different lipoprotein sources in hepatocytes

FY 2018-19

Summary
Atherosclerosis is a chronic progressive disease accounting for most cardiovascular disease cases. It is caused by the accumulation of lipoproteins in the arteries. Components of these lipoproteins, such as cholesterol and protein, form plaques which harden and narrow the arteries. This accumulation can block blood flow. The liver regulates the levels of these atherogenic lipoproteins by altering their release from the liver and their removal from the blood. Liver cells, called hepatocytes, are capable of removing lipoproteins from the bloodstream and then releasing them within the cell. The lipoprotein is then degraded, and its cholesterol is released in the hepatocyte. In theory, the degraded lipoprotein governs intracellular levels of cholesterol. Our work suggests that the outcome of cholesterol regulation depends on the lipoprotein and the cell studied. In hepatocytes, most of the cholesterol from low-density lipoproteins (LDL) is released into the bloodstream within atherogenic lipoproteins. By contrast, chylomicron remnants (CR) regulate cholesterol levels within the hepatocyte. I hypothesize that in the hepatocyte, LDL cholesterol and CR cholesterol are delivered to distinct compartments to carry out different functions. To test this hypothesis, I will observe hepatocytes under a microscope and map the itinerary of LDL and CR cholesterol. In addition, I will identify the tools hepatocytes use to distinguish LDLs from CRs, and the components that process these lipoproteins. Our goal is to characterize lipoprotein metabolism within liver cells to better understand the pathogenesis of atherosclerosis. This project also has the potential to identify drug targets to reduce the levels of atherogenic lipoproteins released, thus broadening the therapeutic window.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406577
Name
Pisaturo Alessandro
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Studying the metabolic pathways of cholesterol from different lipoprotein sources in hepatocytes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acat2; Apob; Atherosclerosis; Bioid; Er; Immunofluorescence; Lentivirus; Liver; Low Density Lipoprotein (Ldl); Mass Spectrometry
Abstract
Atherosclerosis is a chronic progressive disease accounting for most cardiovascular disease cases. It is caused by the accumulation of lipoproteins in the arteries. Components of these lipoproteins, such as cholesterol and protein, form plaques which harden and narrow the arteries. This accumulation can block blood flow. The liver regulates the levels of these atherogenic lipoproteins by altering their release from the liver and their removal from the blood. Liver cells, called hepatocytes, are capable of removing lipoproteins from the bloodstream and then releasing them within the cell. The lipoprotein is then degraded, and its cholesterol is released in the hepatocyte. In theory, the degraded lipoprotein governs intracellular levels of cholesterol. Our work suggests that the outcome of cholesterol regulation depends on the lipoprotein and the cell studied. In hepatocytes, most of the cholesterol from low-density lipoproteins (LDL) is released into the bloodstream within atherogenic lipoproteins. By contrast, chylomicron remnants (CR) regulate cholesterol levels within the hepatocyte. I hypothesize that in the hepatocyte, LDL cholesterol and CR cholesterol are delivered to distinct compartments to carry out different functions. To test this hypothesis, I will observe hepatocytes under a microscope and map the itinerary of LDL and CR cholesterol. In addition, I will identify the tools hepatocytes use to distinguish LDLs from CRs, and the components that process these lipoproteins. Our goal is to characterize lipoprotein metabolism within liver cells to better understand the pathogenesis of atherosclerosis. This project also has the potential to identify drug targets to reduce the levels of atherogenic lipoproteins released, thus broadening the therapeutic window.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pisaturo, Alessandro
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~